Gujarat Themis Biosyn's Credit Ratings Placed on Watch with Negative Implications
Gujarat Themis Biosyn's bank facilities are on Rating Watch with Negative Implications due to major acquisition plans: MBJ for ~₹1,300 crore and Sanofi brands for ~₹1,700 crore. Funding uncertainty, including a ₹1,000 crore QIP, is a concern. The company disputes the rating, citing ignored de-risking measures.
The 'Rating Watch with Negative Implications' and the significant acquisition plans, along with the company's dispute with the rating agency, can have a substantial impact on investor confidence and the company's ability to access future financing.
The credit rating has been placed on 'Rating Watch with Negative Implications' due to concerns about the company's large-scale acquisition plans and funding uncertainty, which directly impacts its credit profile.
CARE Ratings Limited has placed Gujarat Themis Biosyn Limited's (GTBL) long-term bank facilities at 'CARE BBB (RWN)' and short-term bank facilities at 'CARE A3+ (RWN)', indicating a Rating Watch with Negative Implications. This action follows GTBL's announcement of significant acquisition plans, including the acquisition of 100% equity in MicroBiopharm Japan Co., Limited (MBJ) for ¥1.5 Billion (~₹1,300 crore) and a portfolio of anti-tuberculosis and anti-infective brands from Sanofi for €158 million (~₹1,700 crore).
The rating watch reflects concerns regarding the scale of these proposed acquisitions, which are approximately 10 times GTBL's tangible net worth, and the uncertainty surrounding their funding structure. GTBL plans to raise ₹1,000 crore through a Qualified Institutional Placement (QIP), the timely completion of which is critical for the MBJ acquisition. The company has also announced near completion of its capex for a hybrid power generation unit and enhancement of fermentation capacities, along with the commencement of an API unit.
GTBL has expressed strong disagreement with the rating action, stating that the agency has failed to factor in concrete de-risking of liquidity and maturities, including the ongoing QIP funding roadshows. The company argues that the leverage increase due to acquisitions will be offset by increased revenue and EBITDA multiples from the acquired entities. GTBL has requested that its protest and counter-arguments be disseminated alongside the rating rationale.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under credit ratings. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.